Latest Insider Transactions at Altimmune, Inc. (ALT)
This section provides a real-time view of insider transactions for Altimmune, Inc. (ALT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Altimmune, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Altimmune, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 19
2024
|
David Drutz Director |
SELL
Open market or private sale
|
Indirect |
16,011
-14.28%
|
$96,066
$6.91 P/Share
|
|
Aug 19
2024
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
41,750
+27.06%
|
$83,500
$2.55 P/Share
|
|
Jul 31
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
650
+1.48%
|
$3,250
$5.41 P/Share
|
|
Jul 31
2024
|
Andrew Shutterly Acting Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,259
+9.97%
|
$6,295
$5.41 P/Share
|
|
Jul 31
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,486
+2.63%
|
$7,430
$5.41 P/Share
|
|
Jul 31
2024
|
Raymond M Jordt Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
917
+5.89%
|
$4,585
$5.41 P/Share
|
|
Feb 02
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,376
-2.79%
|
$75,384
$9.32 P/Share
|
|
Feb 02
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,950
+5.93%
|
-
|
|
Feb 02
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,332
-4.17%
|
$20,988
$9.32 P/Share
|
|
Feb 02
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+12.2%
|
-
|
|
Feb 02
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,330
-5.18%
|
$20,970
$9.32 P/Share
|
|
Feb 02
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+14.74%
|
-
|
|
Feb 01
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,313
-2.53%
|
$65,817
$9.88 P/Share
|
|
Feb 01
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,545
+5.42%
|
-
|
|
Feb 01
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-3.6%
|
$16,209
$9.88 P/Share
|
|
Feb 01
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+10.98%
|
-
|
|
Feb 01
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-4.62%
|
$16,209
$9.88 P/Share
|
|
Feb 01
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+13.65%
|
-
|
|
Jan 31
2024
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,621
+9.31%
|
$9,242
$2.69 P/Share
|
|
Jan 31
2024
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,889
+2.82%
|
$15,778
$2.69 P/Share
|
|
Jan 31
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,257
+6.92%
|
$6,514
$2.69 P/Share
|
|
Jan 31
2024
|
Raymond M Jordt Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,030
+26.79%
|
$10,060
$2.69 P/Share
|
|
Jan 31
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,860
+15.14%
|
$11,720
$2.69 P/Share
|
|
Jan 30
2024
|
Richard I Eisenstadt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,175
-5.11%
|
$19,575
$9.8 P/Share
|
|
Jan 30
2024
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+17.89%
|
-
|
|
Jan 30
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,697
-4.24%
|
$105,273
$9.8 P/Share
|
|
Jan 30
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,775
+8.84%
|
-
|
|
Jan 30
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,709
-6.26%
|
$24,381
$9.8 P/Share
|
|
Jan 30
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+17.65%
|
-
|
|
Jan 30
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,709
-9.12%
|
$24,381
$9.8 P/Share
|
|
Jan 30
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+23.8%
|
-
|
|
Jan 01
2024
|
Raymond M Jordt Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,503
-22.33%
|
$27,533
$11.25 P/Share
|
|
Jan 01
2024
|
Raymond M Jordt Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+45.55%
|
-
|
|
Dec 29
2023
|
Richard I Eisenstadt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,044
-8.38%
|
$33,484
$11.25 P/Share
|
|
Dec 29
2023
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+25.6%
|
-
|
|
Aug 15
2023
|
David Drutz Director |
BUY
Open market or private purchase
|
Indirect |
300
+1.0%
|
$600
$2.88 P/Share
|
|
Jul 31
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
691
+1.99%
|
$1,382
$2.81 P/Share
|
|
Jul 31
2023
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,825
+7.11%
|
$3,650
$2.81 P/Share
|
|
Jul 31
2023
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
126
+0.05%
|
$252
$2.81 P/Share
|
|
Jul 31
2023
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
568
+2.71%
|
$1,136
$2.81 P/Share
|
|
Jul 31
2023
|
Raymond M Jordt Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,832
+50.0%
|
$3,664
$2.81 P/Share
|
|
Mar 24
2023
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+31.24%
|
$40,000
$4.31 P/Share
|
|
Mar 23
2023
|
David Drutz Director |
BUY
Open market or private purchase
|
Indirect |
9,000
+23.39%
|
$36,000
$4.27 P/Share
|
|
Mar 23
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+23.09%
|
$40,000
$4.22 P/Share
|
|
Feb 02
2023
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,422
-3.27%
|
$126,330
$15.04 P/Share
|
|
Feb 02
2023
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,950
+6.85%
|
-
|
|
Feb 02
2023
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,364
-9.21%
|
$35,460
$15.04 P/Share
|
|
Feb 02
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+23.24%
|
-
|
|
Feb 02
2023
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,375
-10.68%
|
$35,625
$15.04 P/Share
|
|
Feb 02
2023
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+25.91%
|
-
|